Recently, a therapeutic strategy targeting the mTOR-HIF-1α-VEGF pathway in OCCC has been proposed based on the finding that p-mTOR expression is more prominent in OCCC than ovarian serous carcinoma [30]. This evidence concerns the gene MTOR and ovarian serous carcinoma.